JP2015526509A - イルベサルタンおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む医薬複合カプセル製剤 - Google Patents

イルベサルタンおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む医薬複合カプセル製剤 Download PDF

Info

Publication number
JP2015526509A
JP2015526509A JP2015529684A JP2015529684A JP2015526509A JP 2015526509 A JP2015526509 A JP 2015526509A JP 2015529684 A JP2015529684 A JP 2015529684A JP 2015529684 A JP2015529684 A JP 2015529684A JP 2015526509 A JP2015526509 A JP 2015526509A
Authority
JP
Japan
Prior art keywords
irbesartan
hmg
coa reductase
reductase inhibitor
pharmaceutical composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015529684A
Other languages
English (en)
Japanese (ja)
Inventor
キム，ヨン・イル
クウォン，ヨン・ジン
パーク，カレブ・ヒュンミン
リー，スン・ヨプ
パーク，ジェ・ヒュン
ウー，ジョン・スー
Original Assignee
ハンミ ファーム． シーオー．， エルティーディー．
ハンミ ファーム． シーオー．， エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015526509(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ハンミ ファーム． シーオー．， エルティーディー．, ハンミ ファーム． シーオー．， エルティーディー． filed Critical ハンミ ファーム． シーオー．， エルティーディー．
Publication of JP2015526509A publication Critical patent/JP2015526509A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015529684A 2012-08-31 2013-08-30 イルベサルタンおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む医薬複合カプセル製剤 Pending JP2015526509A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020120096036A KR20140030505A (ko) 2012-08-31 2012-08-31 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR10-2012-0096036 2012-08-31
PCT/KR2013/007841 WO2014035190A1 (en) 2012-08-31 2013-08-30 Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor

Publications (1)

Publication Number Publication Date
JP2015526509A true JP2015526509A (ja) 2015-09-10

Family

ID=50183919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529684A Pending JP2015526509A (ja) 2012-08-31 2013-08-30 イルベサルタンおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む医薬複合カプセル製剤

Country Status (28)

Country Link
US (1) US20150231085A1 (enExample)
EP (1) EP2890371A4 (enExample)
JP (1) JP2015526509A (enExample)
KR (1) KR20140030505A (enExample)
CN (1) CN104602678A (enExample)
AR (1) AR092385A1 (enExample)
AU (1) AU2013309688A1 (enExample)
BR (1) BR112015004091A2 (enExample)
CA (1) CA2882738A1 (enExample)
CL (1) CL2015000363A1 (enExample)
CO (1) CO7350622A2 (enExample)
CR (1) CR20150124A (enExample)
DO (1) DOP2015000042A (enExample)
EA (1) EA201590474A1 (enExample)
EC (1) ECSP15010617A (enExample)
IL (1) IL237425A0 (enExample)
IN (1) IN2015DN01738A (enExample)
MA (1) MA37953A1 (enExample)
MX (1) MX2015002591A (enExample)
NI (1) NI201500028A (enExample)
PE (1) PE20150402A1 (enExample)
PH (1) PH12015500395A1 (enExample)
RU (1) RU2015111523A (enExample)
SG (1) SG11201500580QA (enExample)
TW (1) TW201414511A (enExample)
UY (1) UY35000A (enExample)
WO (1) WO2014035190A1 (enExample)
ZA (1) ZA201502157B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528884A (ja) * 2017-07-25 2020-10-01 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する化合物の製剤
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
EP3184103A1 (en) * 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
CN110237070A (zh) * 2019-05-10 2019-09-17 辽宁大学 厄贝沙坦在制备降血脂药物中的应用
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090114328A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
JP2011515445A (ja) * 2008-03-28 2011-05-19 フエルレル インターナショナル，ソシエダッド アノニマ 心臓血管疾患の予防のためのカプセル剤
WO2011142621A2 (en) * 2010-05-14 2011-11-17 Hanmi Holdings Co., Ltd. Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
US9056134B2 (en) * 2010-07-21 2015-06-16 Nucitec S.A. De C.V. Single daily dosage form for prevention and treatment of metabolic syndrome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515445A (ja) * 2008-03-28 2011-05-19 フエルレル インターナショナル，ソシエダッド アノニマ 心臓血管疾患の予防のためのカプセル剤
KR20090114328A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 약제학적 제제
WO2011142621A2 (en) * 2010-05-14 2011-11-17 Hanmi Holdings Co., Ltd. Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528884A (ja) * 2017-07-25 2020-10-01 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する化合物の製剤
JP7170030B2 (ja) 2017-07-25 2022-11-11 プレキシコン インコーポレーテッド キナーゼを調節する化合物の製剤
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用

Also Published As

Publication number Publication date
BR112015004091A2 (pt) 2017-07-04
DOP2015000042A (es) 2015-04-30
RU2015111523A (ru) 2016-10-20
MA37953A1 (fr) 2017-01-31
ECSP15010617A (es) 2015-12-31
MX2015002591A (es) 2015-06-10
KR20140030505A (ko) 2014-03-12
AU2013309688A1 (en) 2015-02-26
US20150231085A1 (en) 2015-08-20
SG11201500580QA (en) 2015-02-27
AR092385A1 (es) 2015-04-22
NI201500028A (es) 2017-01-04
IL237425A0 (en) 2015-04-30
UY35000A (es) 2014-03-31
PH12015500395A1 (en) 2015-04-27
EP2890371A4 (en) 2016-04-06
CL2015000363A1 (es) 2015-06-05
TW201414511A (zh) 2014-04-16
PE20150402A1 (es) 2015-04-13
EP2890371A1 (en) 2015-07-08
CA2882738A1 (en) 2014-03-06
EA201590474A1 (ru) 2015-06-30
IN2015DN01738A (enExample) 2015-05-29
CO7350622A2 (es) 2015-08-10
CR20150124A (es) 2015-04-24
WO2014035190A1 (en) 2014-03-06
ZA201502157B (en) 2016-10-26
CN104602678A (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
CA2798363C (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
JP2015526509A (ja) イルベサルタンおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む医薬複合カプセル製剤
JP6068765B2 (ja) 薬学的複合製剤
KR101171375B1 (ko) 난용성 약물을 함유하는 경구 제형
CN105431140B (zh) 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂
KR101839665B1 (ko) 심혈관 질병의 치료를 위한 경구 제제
KR102314015B1 (ko) 이층정제 및 이의 제조 방법
JP2024023702A (ja) カルシウム拮抗剤及びアンジオテンシンｉｉ受容体拮抗剤を有効成分として含有する錠剤
US20110206761A1 (en) Stable dosage forms of antihypertensive agents
CN110545801A (zh) HMG-CoA还原酶抑制剂以及包含钙通道阻滞剂的复合制剂
KR102042626B1 (ko) 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN119074728A (zh) 用于高血压治疗的多重释放组合物
RU2606592C1 (ru) Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
KR101072600B1 (ko) 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법
HK1181685B (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180710